Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acquired blood coagulation disorders].

H Riess1

  • 1Charité, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Augustenburger Platz 1, 13353 Berlin, Germany.

Hamostaseologie
|November 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism. The revised AWMF S2k Guideline

VASA. Zeitschrift fur Gefasskrankheiten·2023
Same author

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.

Oncoimmunology·2022
Same author

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.

EBioMedicine·2021
Same author

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.

European journal of cancer (Oxford, England : 1990)·2020
Same author

Anticoagulation treatment of cancer patients with deep or superficial leg vein thrombosis - a retrospective observational study of German statutory health insurance claims data (the CERTIFICAT initiative).

VASA. Zeitschrift fur Gefasskrankheiten·2020
Same author

[Thromboprophylaxis in patients with cancer].

Der Internist·2019

Acquired coagulopathies, often from liver failure or sepsis, can be treated by modulating hemostasis. Recent studies confirm this approach reduces mortality in patients with these bleeding disorders.

Area of Science:

  • Hematology
  • Internal Medicine
  • Critical Care Medicine

Context:

  • Acquired coagulopathies frequently arise from underlying conditions like liver failure and sepsis.
  • Identifying the root cause is not always possible, as seen in immunocoagulopathies.
  • Effective management of these conditions is crucial for patient prognosis.

Purpose:

  • To explore the role of therapeutic modulation of hemostasis in managing acquired coagulopathies.
  • To investigate methods for preventing fatal bleeding and thromboembolism in affected patients.
  • To assess the impact of individualized, lab-controlled treatments on patient outcomes.

Summary:

  • Therapeutic modulation of hemostasis can improve outcomes for patients with acquired coagulopathies.

Related Experiment Videos

  • Randomized, placebo-controlled phase III studies have recently validated this approach.
  • This marks a significant advancement in understanding and treating these complex bleeding disorders.

    • Impact:

    • Improved patient prognosis through targeted hemostasis modulation.
    • Reduced mortality rates in acquired coagulopathies.
    • Establishment of evidence-based therapeutic strategies for bleeding disorders.